Cart
sales@molnova.com
Byakangelicin
CAS No. 19573-01-4
Byakangelicin( —— )
Catalog No. M18189 CAS No. 19573-01-4
Byakangelicin is an antineoplastic agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 88 | In Stock |
|
| 10MG | 144 | In Stock |
|
| 25MG | 233 | In Stock |
|
| 50MG | 342 | In Stock |
|
| 100MG | 509 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameByakangelicin
-
NoteResearch use only, not for human use.
-
Brief DescriptionByakangelicin is an antineoplastic agent.
-
DescriptionByakangelicin is an antineoplastic agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number19573-01-4
-
Formula Weight334.32
-
Molecular FormulaC17H18O7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (299.11 mM)
-
SMILESCC(C)([C@@H](COc1c2c(c(c3c1oc(=O)cc3)OC)cco2)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yang J, et al. Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes. Br J Pharmacol. 2011 Jan;162(2):441-51.
molnova catalog
related products
-
Protein kinase inhib...
Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
-
Indolidan
Indolidan (LY 195115) induces cardiovascular and adrenal hyperplastic lesions in Fischer 344 rats. Indolidan increases the risk of cardiovascular disease.
-
Luteolin 7-sulfate
Luteolin 7-sulfate is isolated from Phyllospadix iwatensis Makino, a marine plant. Luteolin 7-sulfate attenuates TYR gene expression through the intervention of a cAMP-responsive element binding protein (CREB)- and microphthalmia-associated transcription factor (MITF)-mediated signaling pathway, leading to the decreased melanin synthesis.
